NASDAQ : TVTX
Travere Therapeutics, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 50.57 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 4.77B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 4.64B |
| Enterprise Value | 4.77B |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 2, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 94.26M |
| Shares Outstanding | 94.26M |
| Shares Change (YoY) | +7.89% |
| Shares Change (QoQ) | +1.75% |
| Owned by Insiders (%) | 1.10% |
| Owned by Institutions (%) | 116.58% |
| Float | 93.22M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | 13.32 |
| PS Ratio | 7.86 |
| Forward PS | 4.90 |
| PB Ratio | 193.52 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 50.11 |
| P/OCF Ratio | 50.11 |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 8.07 |
| EV / EBITDA | 208.31 |
| EV / EBIT | n/a |
| EV / FCF | 51.49 |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 4.05 |
| Quick Ratio | 3.76 |
| Debt / Equity | 25.16 |
| Debt / EBITDA | 22.59 |
| Debt / FCF | 6.65 |
| Interest Coverage | -4.27 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -236.35% |
| Return on Assets (ROA) | -3.73% |
| Return on Invested Capital (ROIC) | -25.77% |
| Return on Capital Employed (ROCE) | -6.25% |
| Weighted Average Cost of Capital (WACC) | 9.44% |
| Revenue Per Employee | $1.19M |
| Profits Per Employee | -$87,453 |
| Employee Count | 497 |
| Asset Turnover | 0.87 |
| Inventory Turnover | 40.46 |
Taxes
| Measure | Value |
|---|
| Income Tax | 605,000 |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 1.14 |
| 52-Week Price Change | +40.10% |
| 50-Day Moving Average | 58.73 |
| 200-Day Moving Average | 46.72 |
| Relative Strength Index (RSI) | 32.34 |
| Average Volume (20 Days) | 2,084,419 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 10.91M |
| Short Previous Month | 12.66M |
| Short % of Shares Out | 11.58% |
| Short % of Float | 11.71% |
| Short Ratio (days to cover) | 5.59 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 591.33M |
| Gross Profit | 350.12M |
| Operating Income | -40.46M |
| Pretax Income | -67.07M |
| Net Income | -43.46M |
| EBITDA | 22.91M |
| EBIT | -40.46M |
| Loss Per Share | -$0.48 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 489.18M |
| Total Debt | 616.91M |
| Net Cash | -127.73M |
| Net Cash Per Share | -$1.36 |
| Equity (Book Value) | 24.52M |
| Book Value Per Share | 0.26 |
| Working Capital | 463.12M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | 92.70M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 63.37M |
| Net Borrowing | 105.21M |
| Free Cash Flow | 92.70M |
| FCF Per Share | $0.98 |
Margins
| Measure | Value |
|---|
| Gross Margin | 59.21% |
| Operating Margin | -6.84% |
| Pretax Margin | -11.34% |
| Profit Margin | -7.35% |
| EBITDA Margin | 3.87% |
| EBIT Margin | -6.84% |
| FCF Margin | 15.68% |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -7.89% |
| Shareholder Yield | -7.89% |
| Earnings Yield | -0.97% |
| FCF Yield | 2.00% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $75.21 |
| Price Target Difference | 52.68% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 15 |
| Revenue Growth Forecast (3Y) | 40.45% |
| EPS Growth Forecast (3Y) | 101.99% |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | 0.76 |
| Piotroski F-Score | 5 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |